MYD88 and diffuse large B-cell lymphoma: CD5+ DLBCL more frequently harbored MYD88 mutations (62.5%, n = 15, P = 0.0189; 13 of 15 with L265P, 1 of 15 with P245L, and 1 of 15 with Q249_K250del), PIM1 mutations (66.7%, n = 16, P = 0.0032; all cases with SNVs, eight of which also had small indels), KMT2D mutations (41.7%, n = 10, P = 0.0173; all with SNVs, eight of which were nonsense mutations), and CDKN2A mutations (23.8%, n = 5, P = 0.0496; 2 of 5 with nonsense mutations and 3 of 5 with deletions).